The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1216-1222

  Dang, Chau ^a   Fornier, Monica ^a   Sugarman, Steven ^a   Troso Sandoval, Tiffany ^a   Lake, Diana ^a   D'Andrea, Gabriella ^a   Seidman, Andrew ^a   Sklarin, Nancy ^a   Dickler, Maura ^a   Currie, Violante ^a   Gilewski, Theresa ^a   Moynahan, Mary Ellen ^a   Drullinsky, Pamela ^a   Robson, Mark ^a   Wasserheit Leiblich, Carolyn ^a   Mills, Nancy ^a   Steingart, Richard ^a   Panageas, Katherine ^a   Norton, Larry ^a   Hudis, Clifford ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TANESPIMYCIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CELLULITIS; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIVERTICULITIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; NAIL INFECTION; OVERALL SURVIVAL; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SINUS BRADYCARDIA; SINUSITIS; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEASIBILITY STUDY; GENE AMPLIFICATION; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; PROGNOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; GENE AMPLIFICATION; HEART; HEART FAILURE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; VENTRICULAR DYSFUNCTION, LEFT;

EID: 41649098657     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.0733     Document Type: Article

References (26)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. US Food and Drug Administration: FDA Clinical Review of BLA 98-0369: Herceptin Trastuzumab (rhuMAb HER2), 1998. http://www.fda.gov/cder/biologics/ review/trasgen092598r1p1.pdf
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
6. Smith I: Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA Trial): Disease-free and overall survival after 2 years median follow-up. Proc Am Soc Clin Oncol 24, 2006
7. Slamon DJ, Eiermann W, Robert NJ, et al: Phase III trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: Second interim analysis of the BCIRG 006 study. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-17, 2006
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
9. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21:976-983, 2003
10. Mamounas EP, Bryant J, Lembersky BC, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP-B 28. J Clin Oncol, 23:3686-3696, 2005
11. Hudis C, Citron ML, Berry D, et al: Five year follow-up of INT C9741: Dose dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res 94:S20, 2005 (suppl 1)
12. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
13. Geyer CE, Yothers G, Romond E, et al: Cardiac safety analysis of the first stage of NSABP B-31: A randomized trial of AC/Taxol with and without Herceptin in women with node-positive HER-2 overexpressing breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003
14. Perez EA. Suman VJ, Davidson PA, et al: Effect of doxorubicin plus cyclophosphamide (AC) on left ventricular ejection fraction (LVEF) in the NCCTG N 9831 Intergroup Adjuvant Trial. Proc Am Clin Oncol 21:19s,2003 (abstr 75)
15. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
16. Geyer CE, Bryant JL, Romond EH, et al: Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs AC → T with trastuzumab (H) Proc Am Soc Clin Oncol 24:18s, 2006 (abstr 581)
17. Perez EA, Suman VJ, Davidson NE, et al: Interim cardiac safety analysis of NCCTG N9831 intergroup adjuvandt trastuzumab trial. Proc Am Clin Oncol 23:17s, 2005 (abstr 556)
18. Perez EA, Suman VJ, Davidson NE, et al: Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Breast Cancer Res 94:S96, 2005 (suppl 1)
19. Rosner, B: Fundamentals of Biostatistics (ed 3). Boston, MA, PWS-Kent Publishing Company, 1990, pp. 82-83
20. Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy wih/without trastuzumab in patients with HER2-positive breast cancer. Proc Am Clin Oncol 25:6s, 2007 (abstr 512)
21. Rastogi P, Jeong J, Geyer CE, et al: Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide (AC) → paclitaxel (T) compared to AC → T with trastuzumab (H). Proc Am Clin Oncol 25:6s, 2007 (abstr LBA513)
22. Gomez H, Chavez M, Doval D, et al: A Phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 23:203s, 2005 (abstr 3046)
23. Storniolo A, Burris H, Pegram M, et al: Phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. Proc Am Clin Oncol 23:18s, 2005 (abstr 559)
24. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
25. Wong KK, Fracasso PM, Bukowski RM, et al: HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: Preliminary phase I results in patients with solid tumors. Proc Am Soc Clin Oncol 24:125s, 2006 (abstr 3018)
26. Modi S, Stopeck A, Gordon MS, et al: Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T). Proc Am Soc Clin Oncol 24:2s, 2006 (abstr 501)